AHP-IRITO 100mg/5ml Injection

AHP-IRITO 100mg/5mL Injection contains Irinotecan 100mg, an anticancer medicine belonging to the topoisomerase I inhibitor class. It is marketed by Al Habib Pharmaceuticals (AHP) and is used as part of chemotherapy regimens for the treatment of certain cancers. Pakistani healthcare procurement records identify AHP-IRITO as Irinotecan 100mg/5mL, while product records identify the manufacturer as Qilu Pharmaceuticals. Irinotecan works by inhibiting the enzyme topoisomerase I, which cancer cells need for DNA replication. By interfering with this process, it helps prevent cancer cells from multiplying and promotes their destruction. It is commonly used in chemotherapy protocols for colorectal cancer and may be combined with other medicines such as fluorouracil, leucovorin, and oxaliplatin depending on the prescribed treatment regimen. AHP-IRITO is administered intravenously by qualified healthcare professionals, usually as part of a planned chemotherapy cycle. The dose is determined by the oncologist based on the cancer type, treatment protocol, body surface area, blood counts, liver function, and overall health. Common side effects include diarrhea, nausea, vomiting, weakness, loss of appetite, mouth sores, and reduced blood-cell counts. Severe or persistent diarrhea and signs of infection require prompt medical attention.

Price: Rs. 12780.00

• Manufacturer
  Al Habib Pharmaceutical
• Generic name
  Irinotecan
• Pack size
  1 Vial injection
• Availability
  In stock
• Prescription required
  Yes